Recent news on Acapodene

GTx Announces Presentation of Ostarineâ„¢ and ACAPODENE® Data at ...  -  25 May 2007
Business Wire (press release),...the ongoing Phase III clinical trial evaluating ACAPODENE® (toremifene citrate) 80 mg for the treatment of multiple side effects of androgen deprivation

Monday's Small-Cap Winners & Losers  -  Apr 30, 2007
TheStreet.comIn the case of GTX, a Leerink Swann & Co. analyst said flaws in an advanced-phase study of the biotech's prostate-cancer treatment, Acapodene,

GTx on brink of major drug breakthroughs  -  May 2, 2007
commercialappeal.com (subscription),It plans to bring two versions of its anti-prostate cancer drug Acapodene to the Food and Drug Administration in 2008 and 2009, and two versions of its

Research and Markets: New Cancer Drug Tracker Acapodene Report ...  -  Apr 17, 2007
Business Wire (press release),...and Markets (http://www.researchandmarkets.com/reports/c54270) has announced the addition of “New Cancer Drug Tracker: Acapodene� to their offering.

GTx to Host an Analyst Day to Provide an Update on Acapodene Phase ...  -  Apr 11, 2007
PharmaLive.com (press release),Dr. Matthew Smith, Associate Professor of Medicine at Harvard Medical School, the Lead Principal Investigator for the Phase III clinical trial of ACAPODENE

GTx's new medical chief to lead Acapodene commercialization  -  Apr 5, 2007
Memphis Business Journal,...and he will provide outstanding medical leadership as we execute our commercialization plans for Acapodene and Ostarine," said Mitchell S. Steiner,

GTx, Inc. Announces First Quarter 2007 Financial Results ...  -  Apr 20, 2007
PharmaLive.com (press release),GTx has licensed to Ipsen Limited exclusive rights in Europe to develop and commercialize ACAPODENE(R). GTx also is developing Ostarine(TM),

GTx, Inc. Announces First Quarter 2007 Financial Results ...  -  Apr 20, 2007
Business Wire (press release),GTx has licensed to Ipsen Limited exclusive rights in Europe to develop and commercialize ACAPODENE®. GTx also is developing Ostarine™, a first-in-class

Market Report -- In Play (GTXI)  -  Apr 18, 2007
MSN MoneyGTX Analyst meeting confirms Acapodene Phase III timelines - Lazard Lazard notes that comprehensive registration strategy for Acapodene and Ostarine

GTx hires to prep for market  -  Apr 10, 2007
commercialappeal.com (subscription),Memphis pharmaceutical company GTx Inc. is in hiring mode as it prepares for a big push next year to bring its experimental prostate cancer drug, Acapodene,

GTx, Inc. Appoints Jeff Hesselberg as Vice President of Regulatory ...  -  Apr 10, 2007
Therapeutics Daily (subscription) (press release),Applications for ACAPODENE and as we advance Ostarine into late stage clinical trials," said Mitchell S. Steiner, MD, Chief Executive Officer of GTx.

Medtronic Buys Swinnea Road Distribution Center  -  Apr 4, 2007
Memphis Daily News,...medical leadership as we execute our commercialization plans for Acapodene and Ostarine," said Dr. Mitchell S. Steiner, GTx CEO, in a statement.

GTx Announces Webcast of Corporate Presentation at the Future ...  -  Mar 22, 2007
PharmaLive.com (press release),GTx has licensed to Ipsen Limited exclusive rights in Europe to develop and commercialize ACAPODENE(R). GTx also is developing Ostarine(TM),

GTx Announces Webcast of Corporate Presentation at the Future ...  -  Mar 22, 2007
Business Wire (press release),GTx has licensed to Ipsen Limited exclusive rights in Europe to develop and commercialize ACAPODENE®. GTx also is developing Ostarine™, a first-in-class

GTx Inc. is a long-term investment for long-term believers  -  Mar 3, 2007
commercialappeal.com (subscription),Its leading drug is Acapodene, which is in late-stage clinical trials involving nearly 3000 patients in Canada, Mexico and the United States.

Market Report -- Short Stories (GTXI)  -  Feb 26, 2007
MSN MoneyThe firm says Acapodene shows positive effect on cholesterol levels among patients treated with androgen deprivation therapy for prostate cancer.

Toremifene claimed to be useful in prostate cancer  -  Feb 26, 2007
Earthtimes.orgORLANDO - Biotech group GTX Inc on Friday claimed that its proposed treatment Acapodene has shown that it can mitigate two of the serious side effects that

Ipsen's Full Year 2006 Results  -  Mar 18, 2007
American Digital Networks (press release),The second, Acapodene(R), will complete our offer of treatment for prostate cancer when the product has obtained the necessary regulatory approvals.

Ipsen s Full Year 2006 Results (12º)  -  Mar 18, 2007
InfoBolsa,...mainly related to payments due within the framework of alliances, such as Acapodene(R) and Increlex(TM), and to acquisition of software, against EUR 7.9

Undiscovered Gem: Hormones Racing at the Speed of Light ...  -  Mar 2, 2007
Schaeffers Research,The company's leading drug candidate, Acapodene, is designed with the goal of preventing men who possess certain precancerous conditions from developing

Treatment With Toremifene Improves Lipid Profile and Bone Mineral ...  -  Feb 27, 2007
DG News...to get a double benefit from the selective oestrogen receptor modulator toremifene (Acapodene), doctors said here at the 3 rd Prostate Cancer Symposium.

GTx's ACAPODENE Interim Bone Mineral Density and Lipid Data ...  -  Feb 23, 2007
PharmaLive.com (press release),ACAPODENE has demonstrated the potential to increase bone mineral density, and the lipid interim analysis shows that ACAPODENE lowers cholesterol and

GTx Announces Presentation of Acapodene Data At ASCO Prostate ...  -  Feb 21, 2007
PharmaLive.com (press release),Both analyses were conducted in the first 197 men to complete one year of treatment in the Phase III clinical trial evaluating ACAPODENE(R) (toremifene

GTX releases positive data for prostate cancer drug  -  Feb 23, 2007
MarketWatchBOSTON (MarketWatch) -- Biotech group GTX Inc. said early Friday that data from a late-stage clinical trial for its proposed treatment Acapodene show the

GTx Inc. stocks up after clinical trial  -  Feb 23, 2007
commercialappeal.com (subscription),GTx researchers said at a conference in Orlando on Friday that an 80 milligram dose of the experimental drug Acapodene helped reduce side effects from

ASCO PROSTATE: Toremifene May Ease Androgen Deprivation Complications  -  Feb 23, 2007
MedPage Today,23 -- The selective estrogen receptor modulator toremifene (Acapodene) improved lipid profiles and increased bone mineral density in androgen deprivation

GTx's Phase III Clinical Development of ACAPODENE on Course ...  -  Feb 2, 2007
Genetic Engineering News (press release),..."This welcome news reduces the risk in ACAPODENE's clinical development. There are more than 350000 patient years of experience with toremifene 60 mg,

GTx stock rises 2% on 4th-quarter report  -  Feb 20, 2007
commercialappeal.com (subscription),Steiner said the company may be able to submit new drug applications to the federal Food and Drug Administration by 2008 for two applications of Acapodene,

GTx's Q4 loss narrows  -  Feb 20, 2007
Memphis Business Journal,Fareston is a chemical cousin of Acapodene, which is nearing the end of two pivotal Phase III clinical studies. Pivotal studies are those expected to lead

GTX Expects Bigger Loss in 2007  -  Feb 20, 2007
Forbes,The financial projection includes continuation of two late-stage clinical trials of Acapodene - for the prevention of prostate cancer - as well as two

UPDATE 1-TABLE-GTx Q4 loss narrows; gives '07 view  -  Feb 20, 2007
ReutersThe outlook includes the continuation of two late-stage Acapodene clinical trials and two mid-stage Ostarine trials which will be initiated this year,

Discovery could help GTx Inc.  -  Feb 14, 2007
commercialappeal.com (subscription),A urine test for high grade PIN would likely mean more men would know they have the condition and would take Acapodene if it ever hits the market, he said.

GTx's development gets nod from safety board  -  Feb 2, 2007
Bizjournals.com,GTx announced Friday that it got a green light from an independent safety review to continue clinical development of its drug Acapodene.

GTx samples help MacroArray find protein marker for prostate cancer  -  Feb 15, 2007
Bizjournals.com,GTx has access to ideal specimens for such a study as it conducts clinical trials of the drug Acapodene. The company has two studies on the drug,

GTx, Inc. Announces Fourth Quarter and Year End 2006 Financial ...  -  Feb 9, 2007
PharmaLive.com (press release),GTx has licensed to Ipsen Limited exclusive rights in Europe to develop and commercialize ACAPODENE(R). GTx also is developing ostarine, a first-in-class

BIO CEO & Investor Conference 2007  -  Feb 7, 2007
Business Wire (press release),GTx has licensed to Ipsen Limited exclusive rights in Europe to develop and commercialize ACAPODENE®. GTx also is developing ostarine, a first-in-class

Biotech Day in Review: Big Pharma Merger in Japan  -  Feb 4, 2007
Seeking Alpha,The Data Safety Monitoring Board has told GTx (GTXI) to continue its pivotal Phase III trial of Acapodene without changing the protocol.

MacroArray Technologies Announces the Identification of a Urine ...  -  Feb 14, 2007
Business Wire (press release),GTx is conducting a pivotal Phase III clinical trial of ACAPODENE® (toremifene citrate) 20 mg for the prevention of prostate cancer in men with high grade

MacroArray Technologies Announces the Identification of a Urine ...  -  Feb 14, 2007
Genetic Engineering News (press release),GTx is conducting a pivotal Phase III clinical trial of ACAPODENE(R) (toremifene citrate) 20 mg for the prevention of prostate cancer in men with high grade

Market Report -- In Play (GTXI)  -  Feb 2, 2007
MSN MoneyData Safety Monitoring Board recommended that GTXI continue clinical development as planned with its two pivotal Phase III clinical trials of Acapodene.

GTx Announces Webcast of Corporate Presentation at the JP Morgan ...  -  Jan 4, 2007
PharmaLive.com (press release),GTx has licensed to Ipsen Limited exclusive rights in Europe to develop and commercialize ACAPODENE(R). GTx also is developing ostarine, a first-in-class

Health interests taking chances  -  Dec 30, 2006
commercialappeal.com (subscription),The company now has two drugs undergoing testing: Acapodene, a drug for two different problems related to prostate cancer, and Ostarine, a drug against bone

GTx Announces Registered Direct Common Stock Offering of $60.8 ...  -  Dec 13, 2006
Earthtimes.orgGTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a ...

GTx drug closer to approval  -  Dec 8, 2006
commercialappeal.com (subscription),...process. In addition to Ostarine, the company is testing a drug called Acapodene against two problems related to prostate cancer. ...

GTx "buy," target price raised  -  Dec 6, 2006
newratings.comGTx’s partner, Ipsen, is expected to file for the EU approval for Acapodene, alongside the drug’s US filing, the analyst says.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional